Mylan FDA Thursday, June 25, 2026 0.00 Neutral

FDA Approves FERRIC CARBOXYMALTOSE — Mylan Institutional LLC

Mylan Institutional LLC’s June 25, 2026 FDA approval for intravenous ferric carboxymaltose is expected to introduce a generic alternative to the market, potentially reshaping the competitive dynamics of intravenous iron therapies.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day